Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Tiotropium (18mcg) Rota Cap
Therapeutic Category
Asthma, Pulmonary, Respiratory
Dosage Form
Rota cap
Packaging Type
in a Bottle
Packaging
30 Capsules
Price
₹366.24/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Tiotropium 18mcg rota capsule is a long-acting bronchodilator used for the effective management of chronic obstructive pulmonary disease (COPD) and bronchospasm, improving airflow and respiratory comfort.
It works by blocking muscarinic receptors in the airways, leading to smooth muscle relaxation, prolonged bronchodilation, and reduced airway constriction.
This rota capsule is commonly prescribed for maintenance therapy in COPD patients, chronic bronchitis, and emphysema, helping decrease breathlessness, wheezing, and frequency of exacerbations.
With clinically proven efficacy, convenient once-daily dosing, and strong prescription acceptance, this formulation strengthens a respiratory therapy portfolio and supports consistent demand in pulmonary care.
Common side effects may include dry mouth, throat irritation, cough, headache, or mild dizziness. Rarely, urinary retention or cardiovascular effects may occur in sensitive patients.
Tioprime 18 Rota Cap is indicated for the maintenance treatment of COPD, including chronic bronchitis and emphysema. It helps control symptoms, improve lung function, and reduce exacerbations, as prescribed by a healthcare professional.
For inhalation use only. Use under strict medical supervision. Not intended for acute bronchospasm relief. Follow proper inhalation technique and keep the inhaler clean as directed.
Store below 25°C in a cool, dry place. Protect from direct sunlight and moisture. Keep out of reach of children.
Composition : Fluticasone Furoate (27.5mcg) + Azelastine (140mcg)
Composition : Fluticasone Furoate (50mcg)
Composition : Fluticasone Furoate (27.5mcg)
Composition : Fluticasone Propionate (0.005% w/v)
Composition : Mometasone (50mcg)
Composition : Xylometazoline (0.1% w/v)
Composition : Xylometazoline (0.05% w/v)
Composition : Sodium Chloride I.P. 0.65% w/v + Benzalkonium Chloride Solution I.P. 0.02% w/v Nasal Drop
Composition : Mometasone Furoate (50mcg) + Azelastine Hydrochloride (140mcg) Nasal Spray
Composition : Calcitonin 200IU Nasal spray
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Tiotropium Rotacaps have strong demand in the respiratory and pulmonology segment, making them a premium chronic-care product for pharma distributors, wholesalers, and franchise partners. It is widely used for COPD (chronic obstructive pulmonary disease), chronic bronchitis, and long-term breathlessness management, ensuring steady prescription-driven demand.
Medical distributors and agencies benefit from the growing burden of chronic respiratory diseases, especially in urban and pollution-affected regions. Long-acting bronchodilator for COPD maintenance therapy Helps improve lung function and reduce breathlessness Once-daily dosing improves patient compliance Widely prescribed by pulmonologists and chest specialists Strong demand in hospital and specialty clinic prescriptions Essential for long-term respiratory disease management This makes it a high-value, steady-moving respiratory care product.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Tiotropium 18 mcg Rotacaps with monopoly rights, promotional support, quality manufacturing standards, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and franchise partners benefit from consistent chronic respiratory prescription demand, strong pulmonology market growth, repeat monthly usage, and stable year-round turnover in the respiratory segment.
Interested distributors, stockists, and pharma franchise partners can contact Cafoli LifeCare Pvt Ltd to discuss monopoly territory rights, pricing structure, marketing support, and complete respiratory product portfolio access to build a strong presence in the COPD and pulmonology market.